OrthoPediatrics Corp (KIDS)
NASDAQ:KIDS
Want to see KIDS full AI Analyst Report?
KIDS Stock Chart & Stats
$16.75
-$0.10(-0.41%)
At close: 4:00 PM EST
$16.75
-$0.10(-0.41%)
Day’s Range― - ―
52-Week Range$14.42 - $23.70
Previous CloseN/A
Volume20.12K
Average Volume (3M)196.93K
Market Cap
$431.76M
Enterprise Value$533.04M
Total Cash (Recent Filing)$50.86M
Total Debt (Recent Filing)$106.28M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 05, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding25,684,994
10 Day Avg. Volume194,659
30 Day Avg. Volume196,931
Financial Highlights & Ratios
PEG Ratio-3.45
Price to Book (P/B)1.20
Price to Sales (P/S)1.76
P/FCF Ratio-26.10
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue2.19
Enterprise Value/Gross Profit3.00
Enterprise Value/Ebitda-44.70
Forecast
1Y Price Target
$24.63Price Target Upside47.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$265.24M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And High Gross MarginsTTM revenue surge combined with ~73% gross margin signals durable product economics and pricing power in a pediatric niche. Sustained top-line growth with high gross margins supports reinvestment in launches, helps absorb SG&A, and underpins a credible path to operating leverage.
EU MDR Approval Enabling EMEA CommercializationFull EU MDR approvals structurally open broader European commercialization across key product lines. This regulatory clearance reduces market access barriers, diversifies revenue away from the U.S., and supports durable international growth and scale efficiencies in EMEA over the medium term.
Product Launch Momentum And Pediatric SpecializationStrong early demand for new pediatric-specific devices and a dedicated pediatric salesforce create a durable competitive position. First-in-market pediatric solutions and higher expected ASPs support stickier surgeon relationships, recurring implant use, and long-term margin expansion as launches scale.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow (TTM) means the business still depends on external capital despite improvements. Continued cash burn constrains strategic flexibility, raises financing and dilution risk, and delays self-funded investment until sustained FCF generation is achieved.
Ongoing GAAP Losses And Negative Net MarginsConsistent GAAP net losses and negative net margins indicate scale has not yet converted to sustained profitability. Reliance on adjusted metrics masks underlying losses; until GAAP profitability is achieved, retained earnings and balance-sheet improvement will be limited, pressuring long-term returns.
Execution And Timing Risks For Launches And Set DeploymentsRevenue, margin expansion, and FCF targets hinge on timely set deployments, regulatory sequencing, and supply logistics. Lower set deployments and higher operating expenses increase the chance that launch or supply delays will defer revenue realization and margin improvement, creating persistent execution risk.
OrthoPediatrics News
KIDS FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
OrthoPediatrics Corp lowest stock price was $14.42 and its highest was $23.70 in the past 12 months.
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is $431.76M.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is Aug 05, 2026 which is in 61 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Apr 30, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.455 by $0.005.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -0.3.
How many shares outstanding does OrthoPediatrics Corp have?
OrthoPediatrics Corp has 25,684,994 shares outstanding.
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.455. Following the earnings report the stock price went up 3.785%.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in KIDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.63 (47.01% Upside)
$24.63 (47.01% Upside)
Blogger Sentiment
Bullish
KIDS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 254.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.43%
12-Months-Change
Fundamentals
Return on Equity
-11.42%
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
KIDS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution and acceleration across several strategic fronts: double-digit revenue growth (13% YoY), a return to positive adjusted EBITDA, >20% OPSB growth, international acceleration, multiple promising beta launches (3P Hip, Vertiglyde) and EU MDR approvals. Management raised full-year revenue guidance and reaffirmed a path to adjusted EBITDA of ~$25M and free-cash-flow breakeven in 2026. Key short-term headwinds and risks include weather-related clinic disruptions that shifted some demand into Q2, continued GAAP/non-GAAP net losses, higher operating expense levels, lower set deployments versus prior-year (by design), and timing uncertainty around set availability and product rollouts. On balance, the strategic momentum, margin improvement and guidance raise outweigh the near-term challenges and execution/timing risks.View all KIDS earnings summariesKIDS Stock 12 Month Forecast
Average Price Target
$24.63
▲(47.01% Upside)
Technical Analysis
Orthofix Medical
―
Tandem Diabetes Care
―
Varex Imaging
―
Bioventus
―
Treace Medical Concepts
―
Ownership Overview
4.32% Insiders
12.67% Mutual Funds
21.93% Other Institutional Investors
53.46% Public Companies and
Individual Investors